ImageneBio (IMA) Enterprise Value (2020 - 2025)
ImageneBio (IMA) posted Enterprise Value of -$135.3 million for Q4 2025, up 5.07% sequentially from -$142.6 million in Q3 2025, and down 318.56% YoY from $61.9 million in Q4 2024.
ImageneBio (IMA) Enterprise Value (2020 - 2025) Analysis & Trends
ImageneBio has reported Enterprise Value for 6 years, with the latest figure at -$135.3 million in Q4 2025.
- Quarterly Enterprise Value fell 318.56% year-over-year to -$135.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$135.3 million (down 318.56% YoY) and the FY2025 annual result came in at -$135.3 million, down 318.56% from the prior year.
- Enterprise Value grew to -$135.3 million in Q4 2025 per IMA's latest filing, from -$142.6 million in the prior quarter.
- Over five years, Enterprise Value peaked at $61.9 million in Q4 2024 and troughed at -$281.0 million in Q1 2021.
- A 5-year average of -$164.7 million and a median of -$157.3 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2021 and 2024: Enterprise Value plunged 340.21% in 2021, then jumped 135.29% in 2024.
- Over 5 years, Enterprise Value stood at -$232.2 million in 2021, then jumped by 32.41% to -$156.9 million in 2022, then dropped by 11.8% to -$175.5 million in 2023, then surged by 135.29% to $61.9 million in 2024, then plunged by 318.56% to -$135.3 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$135.3 million, -$142.6 million, and -$95.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 2.12 Bn |
| 10 | ImageneBio | 48.35 Mn | -87.00 Mn | - | -135.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -135.35 Mn |
| Sep 30, 2025 | -142.58 Mn |
| Jun 30, 2025 | -95.64 Mn |
| Mar 31, 2025 | -114.05 Mn |
| Dec 31, 2024 | 61.93 Mn |
| Sep 30, 2024 | -138.03 Mn |
| Jun 30, 2024 | -145.42 Mn |
| Mar 31, 2024 | -157.35 Mn |
| Dec 31, 2023 | -175.47 Mn |
| Sep 30, 2023 | -196.93 Mn |
| Jun 30, 2023 | -157.31 Mn |
| Mar 31, 2023 | -137.81 Mn |
| Dec 31, 2022 | -156.95 Mn |
| Sep 30, 2022 | -174.36 Mn |
| Jun 30, 2022 | -192.81 Mn |
| Mar 31, 2022 | -212.38 Mn |
| Dec 31, 2021 | -232.22 Mn |
| Sep 30, 2021 | -245.90 Mn |
| Jun 30, 2021 | -264.00 Mn |
| Mar 31, 2021 | -281.01 Mn |